Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrick Schlegel has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ex vivo expansion of autologous, donor-derived NK-, γδT-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity

    by Patrick Schlegel, Anne-Marie Lang, Marie Matela, Annika Horrer, Anne Schilling, Alexander Jöchner, Max Wiedenmann, Christian Seitz, Michaela Döring, Tobias Feuchtinger, et al.

    Posttransplant treatment strategies are narrowed by the vulnerability of bone marrow. Building on immune cells with antitumor activity is a growing field in cancer therapy. Thus, transfer of expanded and preactivated immune cells is a promising intensification of treatment in high-risk tumor patients. We tested ex vivo expanded NK-, gamma delta T-, and CIK cells that were generated by coincubation with irradiated K562-mb15-41BBL and Il2 and compared the expansion conditions of PBMCs versus CD3-depleted PBMCs as well as static versus semi-automated expansion. The median fold expansion was significantly higher using PBMCs and static expansion conditions. Expanded cells were preactivated with a CD56(bright)CD69(high) immunophenotype exerting excellent direct cellular cytotoxicity as well as ADCC in various tumor entities. We established a large-scale clinical-grade ex vivo expansion and activation protocol of NK-, gamma delta T-, and CIK cells from donor-derived PBMCs of patients after haploidentical HSCT. In a patient with AML, NK/gamma delta T/CIK cell transfer was associated with MRD response. A significant increase of direct antitumor activity and ADCC post cell transfer was documented. The results that we report here provide the rationale for clinical testing of expanded, preactivated NK/gamma delta T/CIK cells for cancer therapy.


  • Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation

    by Michaela Döring, Karin Melanie Cabanillas Stanchi, Manon Queudeville, Judith Feucht, Franziska Blaeschke, Patrick Schlegel, Tobias Feuchtinger, Peter Lang, Ingo Müller, Rupert Handgretinger, et al.

    Purpose Paediatric recipients of haematopoietic stem cell transplantation (HSCT) have a high risk for invasive fungal infections. Posaconazole oral suspension has proven to be effective in antifungal prophylaxis in adult and paediatric patients. A new posaconazole tablet formulation with absorption independent of the gastric conditions was approved by the FDA in 2013. This is the first report on the use of posaconazole tablets in paediatric patients. Methods This single-centre study included 63 paediatric patients with haemato-oncological malignancies who received posaconazole for antifungal prophylaxis after HSCT. They were analysed for efficacy, feasibility and the safety of posaconazole. Out of 63 patients, 31 received posaconazole oral suspension and 32 received posaconazole tablets up to 200 days after transplantation. Analyses of the posaconazole trough levels were determined. Results No possible, probable or proven invasive fungal infection was observed in either group. Posaconazole trough levels were significantly higher in the tablet group than in the suspension group at all analysed time points. Drug-related adverse events were similarly low in both groups. Conclusions Posaconazole tablets are effective in preventing invasive fungal infections in paediatric patients. As early as day 3 after starting posaconazole tablets, over 50% of the posaconazole trough levels were >500 ng/mL, while this was observed on day 14 after start with posaconazole suspension. The administration of posaconazole tablets was safe, effective and feasible as antifungal prophylaxis in paediatric patients after HSCT.


  • Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation

    by Lena Oevermann, Peter Lang, Tobias Feuchtinger, Michael Schumm, Heiko‐Manuel Teltschik, Patrick Schlegel, Rupert Handgretinger

    Haploidentical hematopoietic stem cell transplantation is a curative alternative option for patients without an otherwise suitable stem cell donor. In order to prevent graft‐versus‐host disease (GvHD), different in vitro and in vivo T cell–depletion strategies have been developed. A delayed immune reconstitution is common to all these strategies, and an impaired immune function after haploidentical transplantation with subsequent infections is a major cause of deaths in these patients. In addition to in vitro and in vivo T cell–depletion methods, posttransplant strategies to rapidly rebuild the immune system have been introduced in order to improve the outcome. Advances in in vitro and in vivo T cell–depletion methods, and adoptive transfer of immune cells of the innate and specific immune system, will contribute to reduce the risk of GvHD, lethal infections, and the risk of relapse of the underlying malignant disease.


  • Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children

    by Patrick Schlegel, Heiko-Manuel Teltschik, Matthias Pfeiffer, Rupert Handgretinger, Michael Schumm, Ewa Koscielniak, Tobias Feuchtinger, Thomas Klingebiel, Peter Bader, Paul-Gerhard Schlegel, et al.